Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: The pan-american collaborative retina study

Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (IVB) (Avastin; Genentech Inc., San Francisco, CA) (1.25 or 2.5 mg) in patients with subfoveal choroidal neovascularizat...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2010

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/22732

Acceso en línea:

https://doi.org/10.1016/j.ophtha.2010.01.056
https://repository.urosario.edu.co/handle/10336/22732

Palabra clave:

Bevacizumab
Angiogenesis inhibitor
Bevacizumab
Monoclonal antibody
Vasculotropin a
Adult
Aged
Article
Cataract
Drug dose comparison
Drug fatality
Endophthalmitis
Eye examination
Female
Fluorescence angiography
Follow up
Human
Hypertension
Intraocular pressure
Major clinical study
Male
Medical record review
Optical coherence tomography
Priority journal
Retina macula age related degeneration
Retina tear
Retrospective study
Side effect
Stroke
Subretinal neovascularization
Treatment response
Uveitis
Visual acuity
Antagonists and inhibitors
Choroidal neovascularization
Clinical trial
Comparative study
Complication
Injection
Macular degeneration
Middle aged
Multicenter study
Pathophysiology
Physiology
Retina fovea
Time
Very elderly
Vitreous body
Aged
Aged, 80 and over
Angiogenesis inhibitors
Choroidal neovascularization
Female
Fluorescein angiography
Follow-up studies
Fovea centralis
Humans
Injections
Macular degeneration
Male
Middle aged
Retrospective studies
Time factors
Vascular endothelial growth factor a
Visual acuity
Vitreous body
monoclonal
optical coherence
human
monoclonal
humanized
Vegfa protein
Antibodies
Antibodies
Tomography

Rights

License

Abierto (Texto Completo)